Chest
ChestInterleukin-6 Causes Mild Pulmonary Hypertension and Augments Hypoxia-Induced Pulmonary Hypertension in Mice
Section snippets
Methods/Results
Male C57BL/6 mice (weight, 25 g) were treated with daily subcutaneous injections of 200 μg/kg recombinant murine IL-6 and saline solution, and exposed to normoxia or hypobaric hypoxia for 14 days. The animals were killed and right ventricular pressure and RVH were measured. IL-6-treated mice had increased right ventricular pressure (p = 0.08) and RVH (p < 0.05) in normoxia compared to those treated with saline solution. There was no evidence of lung inflammation or vascular thrombosis. During
Conclusions
IL-6 may play an important role in the pathogenesis of PAH. In mice, IL-6 is sufficient to cause PH, and its effects are augmented by hypoxia. IL-6-augmented hypoxic PH is associated with increases in IL-6 and ET-1 levels. Anti-IL-6 therapy may represent a new therapeutic paradigm in the treatment of PAH.
References (0)
Cited by (76)
Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective
2022, Pharmacological ResearchCitation Excerpt :IL-6 is a mechanistic biomarker, indicating the degree of disease in a patient [73]. Delivery of recombinant IL-6 protein in rodents is sufficient to cause pulmonary vascular remodeling [74]. IL-6-mediated immune response also plays an important role in smooth muscle cell dysfunction [75].
Obesity, Systemic Hypertension, and Pulmonary Hypertension: A Tale of Three Diseases
2021, Current Problems in CardiologyTargeting the NLRP3 inflammasome to treat cardiovascular fibrosis
2020, Pharmacology and TherapeuticsDihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats
2017, Biomedicine and PharmacotherapyCitation Excerpt :As one of most commonly used animal models of PAH, the monocrotaline (MCT)-induced rat PAH model is accompanied by abnormal expression levels of inflammatory cytokines, including IL-6, TNF-α, and IL-10 [8–11]. Elevated expression levels IL-6 in plasma have been identified in PAH patients [12], and IL-6 transgenic mice can develop to PAH [13,14]. Matrix metallopeptidase 9 (MMP9) plays an important role in pulmonary arterial remodeling and disease development in various PAH models [15–20].
Interleukin-6 -572C/G polymorphism is associated with serum interleukin-6 levels and risk of idiopathic pulmonary arterial hypertension
2017, Journal of the American Society of HypertensionCitation Excerpt :Second, evidence from lung-specific IL-6 overexpressing transgenic mice showed that IL-6 overexpression replicates the pathologic lesions observed in advanced PAH, including both distal arteriolar muscularization and plexogenic arteriopathy, and leads to increased pulmonary vascular resistance and PAH.9 Third, IL-6 is sufficient to cause pulmonary hypertension in mice, and its effects are augmented by hypoxia.10 Fourth, in the mice with hypoxia-induced pulmonary hypertension, IL-6/IL-21 signaling axis played a critical role in the development of the disease in association with M2 macrophage polarization.11
The role of immune cells and inflammation in pulmonary hypertension: mechanisms and implications
2024, Frontiers in Immunology
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
This research was supported by AHA-SDG 0230255N (Dr. West) and NIH RO1 HL66328 and AHA-EIA 0340122N (Dr. Fagan).